Key result
Cancer patients show rising 1-year CVD incidence after initial declines, driven by a ~136% HF increase.
Why the study?
Comprehensive data on the changing landscape of cardiovascular disease burden in cancer patients remained limited.
Cohort (n=1,322,502)
While cancer-specific mortality has improved, cardiovascular mortality in cancer patients is an increasing concern, driven largely by a rising burden of heart failure.
Answers are grounded in this paper and cite their sources.
May signal need for intensified HF monitoring in cancer survivors; hypothesis-generating for targeted cardio-oncology prevention strategies.
BACKGROUND AND OBJECTIVES: Comprehensive data on the changing landscape of cardiovascular disease (CVD) burden in cancer patients remains limited. We aimed to analyze the temporal trend in the burden of CVD among cancer patients. METHODS: Using a nationwide administrative claims database in Korea, we analyzed 1,322,502 adults (aged ≥18) newly diagnosed with cancer (2005-2022). The primary outcomes were: 1) temporal trends in CVD incidence, including ischemic heart disease (IHD), heart failure (HF), and stroke; and 2) cause-specific mortality trends, focusing on cancer and CVD-related deaths. Both crude and age-standardized rates were calculated for CVD incidence and mortality. RESULTS: The 1-year age-standardized cancer mortality rate showed a substantial decline from 134.0 to 76.3 per 1,000 person-years. While the age-standardized 1-year CVD incidence initially decreased from 91.7 to 50.6 per 1,000 person-years (2005-2014), this improvement plateaued and showed an upward trend thereafter. Analysis of CVD subtypes revealed divergent patterns: age-standardized IHD incidence declined, while HF incidence rose by 136%, 52%, and 37% at 1-, 3-, and 5-year follow-ups. Despite improvements in cancer mortality, the proportion of deaths attributed to CVD increased from 1.0% to 1.5% at 1-year, corresponding to a 50% relative rise and showed a similar upward trend at 5-year follow-up, with HF emerging as an increasingly cause of cardiovascular death (increasing from 10.8% to 26.3% of CVD mortality). CONCLUSIONS: While cancer-specific mortality has improved significantly, cardiovascular mortality remains a growing concern, due to the increasing burden of HF in cancer patients. Ongoing CVD pattern surveillance in cancer patients is crucial for targeted interventions and prevention.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) conducted a cohort in Cancer (n=1,322,502). Time period (2005-2022) was evaluated on Temporal trends in cardiovascular disease incidence and cause-specific mortality. Between 2005 and 2022, 1-year cardiovascular disease incidence in cancer patients initially decreased but later increased, driven by a 136% rise in heart failure incidence.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: